Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind Phase III trial in 62 non-splenectomized chronic ITP patients, 61% 25 of 41 AMG 531
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury